Nanostent was incorporated in Quebec in 2013 as a spin-off company from McGill University. Our focus is on developing innovative miniaturized medical devices for interventional cardiology/radiology and to facilitate operators’ work using a transradial artery approach.

 

We are currently conducting our third round of financing with a goal to raise 7M $ US (equity investment) to support our activities for 2024-2025.

 

Our objectives for 2024-2025 include:

 

1. Launch to OUS & US markets, the Terry2™ band and dedicated digital oximeters. 

2. Submit S3 unique ultra low-profile delivery catheter to FDA (510k) and other regulatory agencies to launch to markets in Q1 2026.

3. Complete pre-clinical work and FIM with our Nano-1 biodegradable metallic stent in F2-316L.